FENTANYL Transdermal System, 12 mcg/h, five (12 mcg/h) systems per carton, Rx only, Distributed b...
FDA Drug Recall #D-1277-2019 — Class I — April 19, 2019
Recall Summary
| Recall Number | D-1277-2019 |
| Classification | Class I — Serious risk |
| Date Initiated | April 19, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Alvogen, Inc |
| Location | Pine Brook, NJ |
| Product Type | Drugs |
| Quantity | 119,608 cartons |
Product Description
FENTANYL Transdermal System, 12 mcg/h, five (12 mcg/h) systems per carton, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058; Manufactured by: 3M Drug Delivery Systems, St. Paul, MN 55107, NDC 47781-423-47.
Reason for Recall
Product Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and containing 50 mcg/h.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot#: 180060, Exp 05/2020; 180073, Exp 06/2020.
Other Recalls from Alvogen, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0259-2026 | Class II | Levothyroxine Sodium Tablets, USP, Thyro-Tabs, ... | Dec 31, 2025 |
| D-0245-2025 | Class I | Fentanyl Transdermal System CII, 25mcg/h, packa... | Jan 31, 2025 |
| D-0353-2023 | Class II | Levothyroxine Sodium Tablets, USP 112 mcg, 90 t... | Feb 6, 2023 |
| D-0649-2021 | Class II | Buprenorphine and Naloxone Sublingual Film 2mg/... | Feb 26, 2021 |
| D-1723-2019 | Class II | Macrobid Urinary Tract Anitbacterial, 100 mg, ... | Jul 24, 2019 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.